Dr. Garzotto is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
3181 SW Sam Jackson Park Rd
Portland, OR 97239Phone+1 503-494-7760Fax+1 503-346-1501
Education & Training
Memorial Sloan Kettering Cancer CenterFellowship, Urologic Surgical Oncology, 1995 - 1999
University of FloridaResidency, Urology, 1992 - 1995- University of FloridaResidency, Surgery, 1990 - 1992
Louisiana State University School of Medicine in New OrleansClass of 1990
Certifications & Licensure
OR State Medical License 2000 - 2025
NY State Medical License 1995 - 2000
FL State Medical License 1992 - 1998
LA State Medical License 1990 - 1990- American Board of Urology Urology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2011-2013
Clinical Trials
- Chemotherapy After Prostatectomy (CAP) For High Risk Prostate Carcinoma Start of enrollment: 2006 Jun 01
- S0421, Docetaxel and Prednisone With or Without Atrasentan in Treating Patients With Stage IV Prostate Cancer and Bone Metastases That Did Not Respond to Previous Hormone Therapy Start of enrollment: 2006 Aug 01
- Radiation Therapy and Docetaxel in Treating Patients Who Are Undergoing Surgery for Localized Prostate Cancer Start of enrollment: 2006 Jan 31
- Join now to see all
Publications & Presentations
PubMed
- 38 citationsPhase I study of weekly DN-101, a new formulation of calcitriol, in patients with cancerTomasz M. Beer, Milind Javle, Christopher W. Ryan, Mark Garzotto, Gilbert N. Lam
Cancer Chemotherapy and Pharmacology. 2007-04-01 - 191 citationsStatins and Prostate Cancer Risk: A Case-Control StudyJackilen Shannon, Selome Tewoderos, Mark Garzotto, Tomasz M. Beer, Rhianna Derenick
American Journal of Epidemiology. 2005-08-15 - 90 citationsCCL2 is induced by chemotherapy and protects prostate cancer cells from docetaxel-induced cytotoxicity.David Z. Qian, Brooks L. S. Rademacher, Janét Pittsenbarger, Chung Ying Huang, Anne Myrthue
The Prostate. 2010-03-01
Press Mentions
Exercise During Prostate Cancer Active Surveillance May Improve CV Risk FactorsAugust 9th, 2024- Extended LND During Radical Cystectomy Offers No Overall Survival EdgeApril 7th, 2023
- EPO No Help for Erectile Dysfunction After Radical ProstatectomyJune 3rd, 2021
- Join now to see all
Grant Support
- P-2: The Effect Of RAD On Androgen Receptor Expression And Activity In ProstateNational Cancer Institute2010–2011
- The Effect Of Radiation On Androgen Receptor Expression And Activity In ProstateNational Cancer Institute2007–2009
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
